During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor). This is a controversial question and one that is being debated by many physicians. We want to include the patient voice in that debate. Please take a few minutes to fill out this brief survey to help us sharing the patient perspective at ASCO. As always, your personal data will not be sharing with anyone. Thank you for taking part!
For the second year in a row, KCCure represented kidney cancer patients at the annual meeting for the American Urological Association. This year, KCCure was instrumental in planning for the meeting by serving on the AUA Steering Committee for Patient Advocacy Efforts.
Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to represent patients on the National Cancer Institute's Genitourinary Steering Committee(GUSC). The primary focus of the committee is to address design prioritization and evaluation of concepts for phase 2 and 3 clinical trials in GU cancers. Her term is effective May 25, 2018 and will last through May 2021.
“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.
KCCure joined with twelve other kidney cancer advocacy organizations urging Congress to double kidney cancer research funding for the Kidney Cancer Research Program (KCRP) administered by the Congressionally Directed Medical Research Program (CDMRP).
Today's Voice of Kidney Cancer is Dr. Elizabeth (Lisa) Henske, who runs the Henske Lab at Brigham and Women's Hospital and Harvard Medical School in Boston. One of her principal areas of research is chromophobe renal cell carcinoma (chRCC). She's also one of the newest members of the KCCure scientific advisory board. We're grateful to Dr. Henske for donating her time to answer a few questions about her work in chRCC.
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder). For the second year in a row, KCCure participated in this important kidney cancer conference.
At KCCure, Kidney Cancer Awareness month is about bringing patients, caregivers, researchers and doctors together to make our collective voice loud and clear. Help us tell the world that this disease exists, that we're fighting and that we need a cure!